1. Kahn RS, Winter-van Rossum I, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018 Aug; pii: S2215-0366(18)30252-9. [PUBMED]
2. Egerton A, Broberg BV, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018 Jun. [PUBMED]
3. Leucht S, Winter-van Rossum I, et al. The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Schizophr Bull. 2015 May; 41(3): 549–558. [PUBMED]
4. Dazzan P, Arango C, et al. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull. 2015 May; 41(3): 574–83. [PUBMED]
5.  Arango C, Kapur S,  et al. Going beyond ''trial-and-error'' in psychiatric treatments: OPTiMiSE-ing the treatment of first episode of schizophrenia. Schizophr Bull. 2015 May; 41(3): 546–8. [PUBMED]
6. Fond G, d'Albis MA, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015 May; 41(3): 559–73. [PUBMED]
7. Drake RJ, Nordentoft, et al. Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. Schizophr Bull. 2015 May; 41(3): 584–96. [PUBMED]
8. Jézéquel J, Rogemond V, et al. Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biol Psychiatry. 2017 Nov; 82(10): 766–772. [PUBMED]
9. Martinuzzi E, Barbosa S, et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry. 2019 Jan 17;9(1):20. doi: 10.1038/s41398-018-0366-5. [PUBMED]
10. Pandit R, Cianci D, et al. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatr Scand. 2019 Sep;140(3):283-290. doi: 10.1111/acps.13074. Epub 2019 Jul 19. [PUBMED]

1. Okhuijsen-Pfeifer C, Huijsman EAH, et al. Kahn RS, Winter-van Rossum I, et al. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand. 2018 Oct;138(4):281-288. doi: 10.1111/acps.12954. Epub 2018 Sep 14. Lancet Psychiatry. 2018 Aug; pii: S2215-0366(18)30252-9. [PUBMED]

2. Okhuijsen-Pfeifer C, Cohen D, et al. Differences between physicians' and nurse practitioners' viewpoints on reasons for clozapine underprescription. 2019 Jul;9(7):e01318. doi: 10.1002/brb3.1318. Epub 2019 May 29.[PUBMED]

  1. Tognin S, van Hell HH, et al. Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. 2019 Aug 19. pii: sbz067. doi: 10.1093/schbul/sbz067. [PUBMED]



1. Bilderbeck AC, Penninx BWJH, et al. Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease. 2019 Feb;97:87-93. doi: 10.1016/j.neubiorev.2018.06.019. Epub 2018 Jun 22. [PUBMED]